- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07694492
Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid
Determining the Feasibility of Utilizing a Medical-Legal Partnership Model to Reach Coal Miners Who Use Tobacco and Nicotine Products and Connect Them to a Pharmacy-based Cessation Program
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Background and rationale. Lung cancer rates are approximately 25% higher in Central Appalachia than in the rest of the U.S., and black-lung mortality has been markedly elevated in the region. Coal miners report the highest rates of cigarette smoking (about 23% vs. ~14% nationally) and smokeless tobacco use (about 23% vs. ~3% nationally) of any U.S. occupation, and TNP use magnifies the risk and severity of obstructive lung disease and lung cancer in this already high-risk group. National guidelines recommend that clinicians refer TNP users to cessation services via ask-advise-connect, but time constraints, limited provider buy-in, and patient factors limit adoption. In workers' compensation cases, claimants must prove their disease results from coal-dust exposure rather than TNP use, which creates both a health and a financial incentive for cessation and gives the miner-lawyer relationship unusual salience. This study leverages that relationship by having lawyers ask about TNP use (already routine at intake), advise quitting, and connect interested clients to a pharmacist-delivered cessation program (the novel component). QuitAid, previously developed and piloted by the study team, is a pharmacist-delivered MTM intervention designed to increase NRT adherence and promote cessation.
Aim 1 (implementation evaluation, lawyers). Guided by the Consolidated Framework for Implementation Research (CFIR), the team evaluates facilitators and barriers to adopting the ask-advise-connect model in approximately three black-lung law offices. Lawyers (up to 5 enrolled) complete baseline and follow-up surveys assessing self-efficacy, attitudes, and perceived facilitators/barriers, and participate in ~30-minute semi-structured telephone interviews (audio-recorded, analyzed thematically). Recruitment feasibility is measured by the proportion of coal miners referred per office and the number enrolled per month. Lawyers are study participants only, not investigators, and referral has no effect on a miner's legal case.
Aim 2 (randomized feasibility pilot, coal miners). Coal miners who use TNPs and have a current black-lung workers' compensation case with a participating law office are referred, screened, and consented by phone, complete a baseline assessment, and are then randomized 1:1 via computer-generated permuted-block randomization (generated in R, embedded in REDCap) to QuitAid (Yes vs. No). All participants receive 24 weeks of NRT beginning in Week 1 regardless of readiness to quit. Participants use of smoked TNPs (cigarettes, e-cigarettes, little cigars, cigarillos, cigars) receive the long-acting NRT patch; those using oral TNPs (smokeless tobacco, nicotine pouches) receive short-acting NRT gum; those using both receive the patch. Participants randomized to QuitAid who are ready to quit receive six telephonic pharmacist coaching sessions over 4 weeks; those not ready to quit receive up to three telephonic Pre-Quit Motivation Modules and may transition to QuitAid if they report readiness at any weekly check-in during Weeks 1-4. If readiness is not reported after four weekly check-ins, QuitAid ends. Follow-up assessments are conducted with all participants at 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks via secure REDCap links or telephone. Because this is a feasibility pilot, secondary clinical outcomes are analyzed descriptively and with logistic regression only to inform a future full-scale trial.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Dylan Allanson, MPH, RD
- Numero di telefono: 4342430424
- Email: da4ac@virginia.edu
Backup dei contatti dello studio
- Nome: Ashley N DeMoss, MPH
- Numero di telefono: (304) 574-8073
- Email: fzv3nn@virginia.edu
Luoghi di studio
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- University of Virginia
-
Sub-investigatore:
- Roger T Anderson, PhD
-
Contatto:
- Ashley N DeMoss, MPH
- Numero di telefono: (304) 574-8073
- Email: fzv3nn@virginia.edu
-
Investigatore principale:
- Melissa A Little, PhD, MPH
-
Investigatore principale:
- Drew Harris, MD
-
Sub-investigatore:
- Candace H Wood, PharmD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Age ≥ 18 years
- Able to read, speak, and understand English
- A coal miner who uses tobacco and nicotine products, lives in the U.S., and has a current black-lung workers' compensation case with a participating law office
- Reports using tobacco and nicotine products daily for the past 6 months
- Willing and able to use NRT in the form of patch or gum
- Not pregnant or planning to become pregnant in the next 6 months
Exclusion Criteria:
- Medical contraindication to NRT (e.g., within the past 30 days: heart attack or stroke; within the past 6 months: serious or worsening angina, or very rapid or irregular heartbeat requiring medication)
- Pregnant or breastfeeding, or planning to become pregnant during the next 6 months
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: QuitAid + NRT
Participants receive the pharmacist-delivered QuitAid MTM program plus 24 weeks of NRT.
Those ready to quit receive six telephonic coaching sessions over 4 weeks; those not ready to quit receive up to three Pre-Quit Motivation Modules and may transition to QuitAid upon reporting readiness at a weekly check-in (Weeks 1-4).
|
Six telephonic pharmacist coaching sessions over 4 weeks focused on setting a quit date and quitting TNPs.
The first session (and subsequent proactive calls at ~days 2, 7, 14, 21, and 28) addresses negative beliefs about NRT, strengthens motivation and commitment to NRT use, monitors NRT use, provides feedback, and supports adherence.
Includes the Pre-Quit Motivation Modules (up to three telephonic sessions) for participants not yet ready to quit.
Altri nomi:
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
|
Comparatore attivo: NRT Only
Participants receive 24 weeks of NRT beginning in Week 1 without the QuitAid MTM program.
All follow-up assessments are conducted regardless of condition.
|
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility of Randomization
Lasso di tempo: Through study recruitment (approximately 6 months)
|
Number of coal miners who need to be approached and screened in order to randomize 100 TNP users.
|
Through study recruitment (approximately 6 months)
|
|
Retention
Lasso di tempo: 26 weeks
|
Proportion of randomized coal miners who complete the 26-week follow-up visit.
|
26 weeks
|
|
Fidelity of Implementation
Lasso di tempo: Through the 4-week intervention period
|
Fidelity of QuitAid delivery, assessed as adherence to QuitAid, quality of program delivery, participant responsiveness, and program differentiation, captured via a session checklist and self-reported end-of-session reflections.
|
Through the 4-week intervention period
|
|
Dose of the Medication Therapy Management (MTM) Intervention
Lasso di tempo: Through the 4-week intervention period
|
Number of MTM (QuitAid) sessions received per participant, documented in the REDCap database.
|
Through the 4-week intervention period
|
|
Dose of NRT
Lasso di tempo: Baseline through 26 weeks
|
Reported proportion of provided NRT that was used by participants.
|
Baseline through 26 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Self-Reported Tobacco Abstinence
Lasso di tempo: 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
Self-reported abstinence, defined as no use of any tobacco or nicotine products within the past 7 days.
|
1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
|
Quit Attempts
Lasso di tempo: Baseline through 26 weeks
|
Number of quit attempts since the previous contact, where a quit attempt is abstinence for ≥24 hours not due to involuntary or forced cessation (e.g., hospitalization).
|
Baseline through 26 weeks
|
|
Frequency of Urges to Use TNPs
Lasso di tempo: Baseline through 26 weeks
|
Self-reported frequency of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
|
Adherence to Assigned Treatment(s)
Lasso di tempo: Baseline through 26 weeks
|
Percentage of intervention sessions completed and percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Adherence to NRT
Lasso di tempo: Baseline through 26 weeks
|
Adherence to NRT (patch or gum), measured as the percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Strength of urges to use TNPs
Lasso di tempo: Baseline through 26 weeks
|
Self-reported strength of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Program satisfaction
Lasso di tempo: 26 weeks
|
Participant-reported barriers to treatment utilization, satisfaction with treatment components, and suggestions for improvement, with items focused on perceived capacity and opportunity to engage with the interventions.
|
26 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Melissa A Little, PhD, MPH, University of Virginia
- Investigatore principale: Drew Harris, MD, University of Virginia
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- terapia sostitutiva della nicotina
- Smettere di fumare
- retribuzione dei lavoratori
- Lawyers
- medical-legal partnership;
- ask-advise-connect
- pharmacist-delivered intervention
- coal miners
- medication therapy management (MTM)
- QuitAid
- tobacco and nicotine products
- Central Appalachia
- black lung
- feasibility pilot
Termini MeSH pertinenti aggiuntivi
- Disordini mentali
- Malattie delle vie respiratorie
- Malattie polmonari
- Disturbi Correlati a Sostanze
- Disturbi indotti chimicamente
- Malattie polmonari, interstiziale
- Lesione polmonare
- Pneumoconiosi
- Comportamento
- Comportamento sanitario
- Disturbo da uso di tabacco
- Smettere di fumare
- Cessazione dell'uso del tabacco
- Antracosi
- Amministrazione dei servizi sanitari
- Terapie
- Terapia farmacologica
- Servizi sanitari
- Force di lavoro e servizi per le strutture sanitarie
- Economia e organizzazioni sanitarie
- Gestione dell'assistenza al paziente
- Finanziamento, organizzato
- Economia
- Servizi Farmaceutici
- Medicare Part D
- Assicurazione, Servizi Farmaceutici
- Assicurazione sanitaria
- Assicurazione
- Medicare
- Terapia sostitutiva di nicotina
- Gestione della Terapia Farmacologica
Altri numeri di identificazione dello studio
- HSR 303071
- 5P30CA044579-30 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su QuitAid (pharmacist-delivered MTM)
-
University of VirginiaAttivo, non reclutante
-
University of VirginiaReclutamentoFumare | Smettere di fumare | Riduzione del fumo | Fumo, tabacco | Fumo, sigaretta | Smettere di fumareStati Uniti